Amgen Inc. Surpasses Expectations, Stock Climbs to 52‑Week High
Amgen Inc. (NASDAQ: AMGN) closed the trading day on February 4, 2026, at $338.59 per share, a level that touches the 52‑week high of $353.25 set on January 26, 2026. The rise in price—up 7.36 % from the previous close—was accompanied by a surge in analyst optimism and institutional activity.
Earnings Beat and Revenue Growth
The company’s most recent fourth‑quarter earnings call, released after the market close, highlighted a 9 % revenue increase to $9.9 billion, and a $1.3 billion rise in net earnings, effectively more than doubling profit expectations. Analysts had projected lower figures, and the guidance for the fiscal year now points to a revenue range of $37.0 billion to $38.4 billion. These results stem from robust sales of Amgen’s blockbuster portfolio, with 14 products cited as significant revenue contributors.
Analyst Upgrades and Price Targets
In line with the earnings beat, Cantor Fitzgerald lifted its price target for AMGN to $350 per share. The new target reflects confidence in the company’s ability to sustain growth momentum and manage competitive pressures. Zacks also noted that the stock’s recent ascent to a 52‑week high could signal a bullish trend for the broader biotechnology sector.
Institutional Buying Activity
The trading day saw notable institutional purchases. Busey Bank acquired 966 shares, TD Waterhouse Canada Inc. bought 2,422 shares, and Zurich Cantonal Bank purchased 55,333 shares. These moves suggest that institutional investors are positioning for a continued upward trajectory, bolstered by Amgen’s strong quarterly performance.
Strategic Outlook
Amgen remains focused on its core strengths in human therapeutics and cellular/molecular biology. The company’s strategic emphasis on high‑impact medicines, combined with ongoing pipeline development, positions it well to address both current therapeutic needs and future market opportunities. The announcement of a shift in the read‑through schedule for pelacarsen to mid‑2026—highlighted by Bank of America in its commentary—underscores the company’s active pipeline management and potential for new product launches.
Market Context
With a market capitalization of $182 billion and a price‑earnings ratio of 26.3, Amgen sits comfortably within the high‑growth biotechnology segment of the Nasdaq. Its recent performance aligns with broader market trends that favor companies delivering tangible clinical and financial results in the life sciences arena.
This article summarizes publicly available financial news and company fundamentals for Amgen Inc. as of February 4, 2026. All figures and statements are sourced from the provided input.
